Rosalie supports clients focused on clinical development, FDA engagement and filing, and broader lifecycle management strategies for drugs, biologics and medical devices.
Before joining Avalere, Rosalie conducted oncology research on drug target validation and preclinical development of small molecules. Previously, she contributed to market research and therapeutic landscape reports during her internship at ATP Ventures Partners. She also competed in the Merck KGaA Innovation Cup, developing a proprietary cancer therapeutic pitch for pharmaceutical executives.
Rosalie holds a PhD in medicinal chemistry from Virginia Commonwealth University and a BS in chemistry from the University of Virginia.
Authored Content
A detailed Avalere report offers insights into state-specific statutes guiding commercial payer coverage for off-label use of oncology drugs/biologics.
A second Trump administration and Republican Congress will mark a shift in healthcare policy priorities in 2025 on both legislative and regulatory fronts.